doi: 10.1161/CIRCULATIONAHA.109.192588
(Circulation. 2009;119:e605.)
© 2009 American Heart Association, Inc.
Correction
In the ADA/ACCF/AHA scientific statement by Skyler et al, "Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association," which published ahead of print on December 17, 2008, and appeared in the January 20, 2009, issue (Circulation. 2009;119;351–357), a correction was needed.In the Acknowledgments on page 356, Dr Richard Bergenstal’s disclosure read, "Dr Bergenstal reports no financial dualities and is an ACCORD investigator." It should have read, "Dr Bergenstal participates in clinical research or has served on a scientific advisory board for Amylin, Merck, Pfizer, ResMed, Valeritas, Eli Lilly, Novo Nordisk, sanofi-aventis, MannKind, Intuity, Roche, LifeScan, Abbott, Bayer, and Medtronic. Dr Bergenstal receives no personal compensation for these activities; all contracts are through the nonprofit Park Nicollet Institute. Dr Bergenstal holds stock in Merck through a family inheritance and is an officer within the American Diabetes Association."
This correction has been made to the current online version of the article, which is available at http://circ.ahajournals.org/cgi/content/full/119/2/351.
| ||||||||||||||||||||||||||||||||||||||